Table 2 Univariate analysis of the overall survival and progression-free survival in 886 patients with invasive breast cancer

From: Clinical significance of CD151 overexpression in subtypes of invasive breast cancer

 

Overall survival

Disease-free survival

Prognostic factor

Number of events Hazard ratio (95% CI)

P -value

Number of events Hazard ratio (95% CI)

P -value

CD151 expression

 Low

90/759

 

177/759

 

 High

35/127

<0.001

41/127

0.021

 

2.50 (1.688-3.687)

 

1.50 (1.064-2.099)

 

AJCC stage

 I

10/237

 

31/237

 

 II

54/444

0.001

93/444

0.013

 

3.00 (1.526-5.883)

 

1.67 (1.114-2.512)

 

 III

61/205

<0.001

94/205

<0.001

 

8.09 (4.416-15.79)

 

4.32 (2.879-6.489)

 

Subtype

 Luminal A

38/451

 

102/451

 

 Luminal B

18/113

0.017

36/113

0.020

 

1.98 (1.131-3.471)

 

1.57 (1.073-2.294)

 

 HER2

28/106

<0.001

33/106

0.027

 

3.30 (2.020-5.376)

 

1.56 (1.053-2.309)

 

 TNBC

41/216

<0.001

47/216

0.858

 

2.39 (1.533-3.712)

 

1.03 (0.730-1.458)

 

Adjuvant chemotherapy

 No

33/148

 

30/148

 

 Yes

92/738

0.009

188/738

0.223

 

0.59 (0.394-0.874)

 

1.27 (0.864-1.868)

 
  1. Abbreviations: AJCC=American Joint Committee on Cancer; CI=confidence interval; HER2=human epidermal growth factor receptor 2; TNBC=triple-negative breast cancer. Statistically significant P-values (P<0.05) are shown in bold.
Back to article page